
|Videos|October 2, 2020
Bayer discusses relevant clinical study results
Author(s)Modern Retina Staff
Patrick Bussfeld, MD, VP, head medical affairs ophthalmology at Bayer Consumer Care AG, discusses the results from several treat-and-extend studies on aflibercept, and how Bayer is participating in the 2020 EURETINA virtual meeting.
Advertisement
Patrick Bussfeld, MD, VP, head medical affairs ophthalmology at Bayer Consumer Care AG, discusses the results from several treat-and-extend studies on aflibercept, and how Bayer is participating in the 2020 EURETINA virtual meeting.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Modern Retina
1
CTS 2026: OTX-TKI demonstrates superiority over aflibercept in wet AMD—what the SOL-1 data mean for retina practice
2
Ranluspec FDA approval: Cyrus Karkaria, PhD, on biosimilar access, prefilled syringes, and long-term switching confidence
3
StemSight gains patent for off-the-shelf limbal stem cell platform patent milestone for STE-101
4
Phase 3 NORTHSTAR trial launches for gildeuretinol in stargardt disease
5




















